> top > docs > PubMed:12560435 > annotations

PubMed:12560435 JSONTXT

Annnotations TAB JSON ListView MergeView

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-90 Sentence denotes HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer.
TextSentencer_T2 91-99 Sentence denotes PURPOSE:
TextSentencer_T3 100-273 Sentence denotes Human epidermal growth factor receptor 2 (HER2) overexpression was found to predict a good response in breast carcinoma patients treated with doxorubicin (Adriamycin [ADM]).
TextSentencer_T4 274-435 Sentence denotes Evidence from our recent study indicates that node-positive patients respond to cyclophosphamide, methotrexate, and fluorouracil (CMF) regardless of HER2 status.
TextSentencer_T5 436-663 Sentence denotes We address the issue of whether therapy regimens including CMF and ADM versus CMF alone have the same therapeutic effect in patients with HER2+ and HER2- tumors in terms of relapse-free survival (RFS) and overall survival (OS).
TextSentencer_T6 664-672 Sentence denotes METHODS:
TextSentencer_T7 673-821 Sentence denotes Archival specimens of the primary tumors from 506 patients in a prospective clinical trial were stained with the anti-HER2 monoclonal antibody CB11.
TextSentencer_T8 822-983 Sentence denotes Originally, patients were randomly allocated to receive either 12 courses of intravenous CMF or eight courses of the same regimen followed by four cycles of ADM.
TextSentencer_T9 984-1198 Sentence denotes RFS and OS were analyzed by a Cox model taking into account treatment, HER2 status, and the interaction between treatment and HER2 status, adjusting for the effect of other known clinical and biopathologic factors.
TextSentencer_T10 1199-1207 Sentence denotes RESULTS:
TextSentencer_T11 1208-1338 Sentence denotes Analysis of survival rates indicates a possible differential effect of treatment in the patients grouped according to HER2 status.
TextSentencer_T12 1339-1446 Sentence denotes Improved RFS and OS were observed in the HER2+ subgroup after treatment with CMF plus ADM versus CMF alone.
TextSentencer_T13 1447-1564 Sentence denotes With a median follow-up of 15 years, the hazard ratio (HR) for RFS was 0.83 in HER2+ tumors and 1.22 in HER2- tumors.
TextSentencer_T14 1565-1695 Sentence denotes The effect of treatment was more evident on OS in HER2+ patients (HR = 0.61; CI, 0.32 to 1.16) than in HER2- patients (HR = 1.26).
TextSentencer_T15 1696-1707 Sentence denotes CONCLUSION:
TextSentencer_T16 1708-1800 Sentence denotes Our data indicate that adding ADM to CMF might be beneficial for patients with HER2+ tumors.
T1 0-90 Sentence denotes HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer.
T2 91-99 Sentence denotes PURPOSE:
T3 100-273 Sentence denotes Human epidermal growth factor receptor 2 (HER2) overexpression was found to predict a good response in breast carcinoma patients treated with doxorubicin (Adriamycin [ADM]).
T4 274-435 Sentence denotes Evidence from our recent study indicates that node-positive patients respond to cyclophosphamide, methotrexate, and fluorouracil (CMF) regardless of HER2 status.
T5 436-663 Sentence denotes We address the issue of whether therapy regimens including CMF and ADM versus CMF alone have the same therapeutic effect in patients with HER2+ and HER2- tumors in terms of relapse-free survival (RFS) and overall survival (OS).
T6 664-672 Sentence denotes METHODS:
T7 673-821 Sentence denotes Archival specimens of the primary tumors from 506 patients in a prospective clinical trial were stained with the anti-HER2 monoclonal antibody CB11.
T8 822-983 Sentence denotes Originally, patients were randomly allocated to receive either 12 courses of intravenous CMF or eight courses of the same regimen followed by four cycles of ADM.
T9 984-1198 Sentence denotes RFS and OS were analyzed by a Cox model taking into account treatment, HER2 status, and the interaction between treatment and HER2 status, adjusting for the effect of other known clinical and biopathologic factors.
T10 1199-1207 Sentence denotes RESULTS:
T11 1208-1338 Sentence denotes Analysis of survival rates indicates a possible differential effect of treatment in the patients grouped according to HER2 status.
T12 1339-1446 Sentence denotes Improved RFS and OS were observed in the HER2+ subgroup after treatment with CMF plus ADM versus CMF alone.
T13 1447-1564 Sentence denotes With a median follow-up of 15 years, the hazard ratio (HR) for RFS was 0.83 in HER2+ tumors and 1.22 in HER2- tumors.
T14 1565-1695 Sentence denotes The effect of treatment was more evident on OS in HER2+ patients (HR = 0.61; CI, 0.32 to 1.16) than in HER2- patients (HR = 1.26).
T15 1696-1707 Sentence denotes CONCLUSION:
T16 1708-1800 Sentence denotes Our data indicate that adding ADM to CMF might be beneficial for patients with HER2+ tumors.

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
12560435-0#0#4#gene2064 0-4 gene2064 denotes HER2
12560435-0#76#89#diseaseC0006142 76-89 diseaseC0006142 denotes breast cancer
12560435-0#76#89#diseaseC0678222 76-89 diseaseC0678222 denotes breast cancer
12560435-1#167#170#gene133 267-270 gene133 denotes ADM
12560435-1#103#119#diseaseC0678222 203-219 diseaseC0678222 denotes breast carcinoma
0#4#gene206476#89#diseaseC0006142 12560435-0#0#4#gene2064 12560435-0#76#89#diseaseC0006142 associated_with HER2,breast cancer
0#4#gene206476#89#diseaseC0678222 12560435-0#0#4#gene2064 12560435-0#76#89#diseaseC0678222 associated_with HER2,breast cancer
167#170#gene133103#119#diseaseC0678222 12560435-1#167#170#gene133 12560435-1#103#119#diseaseC0678222 associated_with ADM,breast carcinoma

DisGeNet-2017-sample

Id Subject Object Predicate Lexical cue
T2750 0-4 gene:2064 denotes HER2
T2751 76-89 disease:C0006142 denotes breast cancer
R1 T2750 T2751 associated_with HER2,breast cancer
R2 T2750 T2751 associated_with HER2,breast cancer

UBERON-AE

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 76-82 http://purl.obolibrary.org/obo/UBERON_0000310 denotes breast
PD-UBERON-AE-B_T2 203-209 http://purl.obolibrary.org/obo/UBERON_0000310 denotes breast

performance-test

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 76-82 http://purl.obolibrary.org/obo/UBERON_0000310 denotes breast
PD-UBERON-AE-B_T2 203-209 http://purl.obolibrary.org/obo/UBERON_0000310 denotes breast

DisGeNET

Id Subject Object Predicate Lexical cue
T0 0-4 gene:2064 denotes HER2
T1 76-89 disease:C0678222 denotes breast cancer
T2 0-4 gene:2064 denotes HER2
T3 76-89 disease:C0006142 denotes breast cancer
T4 267-270 gene:133 denotes ADM
T5 203-219 disease:C0006142 denotes breast carcinoma
T6 142-146 gene:2064 denotes HER2
T7 203-219 disease:C0678222 denotes breast carcinoma
T8 142-146 gene:2064 denotes HER2
T9 203-219 disease:C0006142 denotes breast carcinoma
T10 267-270 gene:133 denotes ADM
T11 203-219 disease:C0678222 denotes breast carcinoma
T12 100-140 gene:2064 denotes Human epidermal growth factor receptor 2
T13 203-219 disease:C0678222 denotes breast carcinoma
T14 100-140 gene:2064 denotes Human epidermal growth factor receptor 2
T15 203-219 disease:C0006142 denotes breast carcinoma
R1 T0 T1 associated_with HER2,breast cancer
R2 T2 T3 associated_with HER2,breast cancer
R3 T4 T5 associated_with ADM,breast carcinoma
R4 T6 T7 associated_with HER2,breast carcinoma
R5 T8 T9 associated_with HER2,breast carcinoma
R6 T10 T11 associated_with ADM,breast carcinoma
R7 T12 T13 associated_with Human epidermal growth factor receptor 2,breast carcinoma
R8 T14 T15 associated_with Human epidermal growth factor receptor 2,breast carcinoma